Pentagastrin

Pharmaceutical

Pentagastrin is a synthetic pentapeptide designed to reproduce the biologically active C-terminal region of the natural hormone gastrin. Because gastrin's activity resides in its terminal amino acids, a short five-residue analog is sufficient to activate the gastrin (CCK2) receptor and mimic gastrin's physiological effects. Marketed historically under the trade name Peptavlon, pentagastrin was developed as a diagnostic agent rather than a treatment. Its most established use was as a provocative stimulus to measure the stomach's capacity to secrete acid: administered to a patient, it activates the same acid-secreting machinery that endogenous gastrin controls, allowing clinicians to quantify maximal and peak acid output in tests of gastric secretory function. Gastric acid secretion testing with pentagastrin was once an important part of evaluating conditions such as suspected acid hypersecretion (for example in Zollinger-Ellison syndrome) and in assessing the completeness of surgical procedures intended to reduce acid production. Pentagastrin acts on the CCK2 (gastrin) receptor, stimulating enterochromaffin-like (ECL) cells to release histamine and thereby driving parietal cell acid output, faithfully reproducing gastrin's mechanism. Over time, however, the clinical role of gastric acid analysis declined substantially with the advent of highly effective acid-suppressing drugs and better serological and endoscopic diagnostics, and pentagastrin was withdrawn or discontinued in many markets. A second notable application was as a provocation test in endocrinology. Pentagastrin stimulates the release of calcitonin from thyroid C-cells, and the pentagastrin-stimulated calcitonin test was historically used to help diagnose and monitor medullary thyroid cancer, a calcitonin-producing tumor, and to evaluate related conditions. This too has largely been superseded — sensitive basal calcitonin assays and modern imaging have replaced pentagastrin provocation in most settings, and availability of the agent itself has become limited. Today pentagastrin is best understood as a historically important diagnostic peptide whose clinical use has faded. It is not a therapeutic drug and is not used for treatment, appetite, or performance purposes; in the United States it is effectively research-only given its discontinuation. Pentagastrin remains a clear illustration of how a short synthetic analog can capture the full activity of a larger natural hormone, and it is most usefully studied alongside gastrin (the hormone it imitates), secretin (its physiological counterpart in acid–secretion regulation), and other synthetic peptide diagnostics such as the growth hormone stimulation agent macimorelin, which similarly harnesses a peptide's pharmacology for a diagnostic purpose.